Bangkok Genomics Innovation Public Company Limited (BKGI), a promising IPO company, has sold 160 million shares, strengthening its status as a stock. Real biotechnology! Preparing to trade on the Stock Exchange of Thailand (SET) on March 20, 2024, Sompop Kirasunthornphong, Managing Director of Finansia Syrus Securities, as Financial Advisor and Distribution Leader. We believe the IPO price of 1.63 baht per share is the right price. Moreover, it is a stock with high growth potential. Showcasing the highlights of the medical genomics industry, an innovative treatment for the future. In addition, major shareholders, both China and Thailand, are voluntarily locking up partners who do not install periodic sirens in accordance with all SET standards for one year. CEO Dr. Sawalak Dansakul said the market value of medical treatments is the medicine of the future. The Thai economy is expected to rise in 2030 to 58 billion baht, with an average annual growth of 16.4%, or a 4-fold increase from 2021.
Mr. Sompop Kirasunthonphong General Manager Finansia Syrus Securities Public Company Limited, in its capacity as financial advisor and underwriter for the Bangkok Genome IPO, disclosed the subscription of 160 million BKGI IPO shares with a nominal value of 0.50 baht at a price of 1.63 baht per share in the period From 12 to 14 March 2024 and has received great interest from investors. This is because investors are confident about BKGI's fundamentals as a stock. The first biotech company in Thailand to raise funds and list on the stock exchange. The spotlight is on the medical genomics industry, which is considered the therapeutic innovation of the future. Furthermore, the product brand is widely known and accepted by both partners and service users. .
In addition, there is a feature from BGI Group, a global provider of genetic decoding services. is a major shareholder and own innovation willing to transfer technology and research as well as give importance to BKGI as a leading company to support its market expansion plans in the ASEAN region. This will help support the future performance of the company to grow significantly.
In this regard, the major shareholders namely the Thai people and BGI Group voluntarily refused to sell the remaining shares due to the embargo period. (Siren period) is all for one year to build confidence for investors.
The fact is that BKGI shares have received attention from investors because the share price has been set at a suitable level with strong fundamentals, and BKGI is preparing to trade on the Stock Exchange of Thailand (SET) on March 20, 2024, using the abbreviation “SET”. Trading as “BKGI” in the Services/Medical category
The medical industry, or genomics, or the analysis of the genetic sequences of living organisms, is life, said Dr. Sawalak Dhansakul, CEO of Bangkok Genomics Innovation Public Limited (BKGI). There is a trend of continued growth. Krungthai COMPASS Research Center estimates that in 2030, the Thai genomics market will be worth US$1.7 billion, or approximately 58 billion baht, with an average annual growth of 16.4%, or a 4-fold increase from 2021.
In this regard, BKGI's revenues from reproductive health services during 2020-2023 achieved an average growth rate of 23.40% per year.
“BKGI's business has the opportunity to grow significantly. As it is an industry witnessing a huge global trend, BKGI can provide screening services. Genetic screening at all pre-conception ages, infectious disease cluster analysis and other genetics-related analysis. Brands include NIFTY, VISTA, NOVA and BGI-XOME , COLOTECT, SENTIS and DNALL, which are accepted by partners and service users.
In addition, the company has strengths through the presence of BGI, a global genetic decoding service provider. In transferring NGS (Next Generation Sequencing) technology and receiving support from BGI Group in various fields to support expansion plans in foreign markets in the future, which is considered new growth for BGI.
BKGI provides medical analysis services. This is done using modern scientific technology transferred from BGI Group, which is one of the main shareholders. It is one of the world's leading companies in genetic decoding for use in developing BKGI analysis to ensure that the Thai population enjoys better and sustainable health in the future.
According to the nature of the work, it can be divided into two types: 1. Laboratory testing and analysis services work, which is divided into 4 types: 1) Screening for genetic abnormalities in reproductive health 2) Analysis of infectious disease groups, such as testing the genetic material of the cause of the Covid-19 disease. 3) Other screening tests include checking gene sets associated with cancer. Detection of other genetic diseases and 4) provision of technology services
2. Businesses that sell other products such as sample collection equipment kits. Coronavirus (COVID-19) testing solution. COVID-19 immunity testing reagents and equipment kits for comprehensive genetic abnormality testing, etc., including in the future nutritional supplements will be sold. For clients using detailed genetic decoding services for individuals as advised by their physician
“Reader. Infuriatingly humble coffee enthusiast. Future teen idol. Tv nerd. Explorer. Organizer. Twitter aficionado. Evil music fanatic.”